Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,079 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Neoadjuvant therapy Clear all
Terminated Phase 1Phase 2 Interventional Results available

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

NCT02440568
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Idarubicin, Omacetaxine mepesuccinate
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT02180867
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

NCT04849364
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Capecitabine, Talazoparib, Pembrolizumab, Inavolisib
Drug
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

NCT02815397
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Metformin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

NCT05877859
View directory record Official record
Conditions
Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Not applicable Interventional Results available

Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma

NCT00430027
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
Capecitabine, Oxaliplatin, Cetuximab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 30, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy

NCT05049746
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Discussion, Interview, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed No phase listed Observational

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

NCT02743910
View directory record Official record
Conditions
Breast Cancer
Interventions
ptDNA, Tissue sample
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

NCT02510014
View directory record Official record
Conditions
Opioid Use Disorder, Opioid-related Disorders
Interventions
SUBOXONE sublingual film, RBP-6000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
42
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated No phase listed Observational

Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus

NCT02991547
View directory record Official record
Conditions
Adenocarcinoma Esophagus
Interventions
Observational
Other
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Corning, New York • Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

NCT05800600
View directory record Official record
Conditions
Anemia
Interventions
Venofer
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Active, not recruiting Phase 2 Interventional

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

NCT00877500
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions
Best Practice, Ixabepilone
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
3
States / cities
Oak Lawn, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

NCT05498272
View directory record Official record
Conditions
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions
Olaparib, LHRH agonist
Drug
Lead sponsor
Rana McKay, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Enrolling by invitation Phase 1 Interventional

Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy

NCT05973734
View directory record Official record
Conditions
Islet Transplantation
Interventions
Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived Vertebral Bone Marrow
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

NCT06833502
View directory record Official record
Conditions
Breast Cancer, Node-positive Breast Cancer
Interventions
CT Scan
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Withdrawn Phase 1Phase 2 Interventional

INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients

NCT00455039
View directory record Official record
Conditions
Breast Cancer
Interventions
GW572016
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Phase 1 Interventional Results available

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

NCT03300544
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Radiation Therapy, Talimogene Laherparepvec
Drug · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00293332
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, docetaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Oct 30, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional

Tc99m Sestamibi Molecular Breast Imaging

NCT02324387
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging (MBI), Tc99m sestamibi
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

NCT04832854
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT05825066
View directory record Official record
Conditions
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine, Radiological Assessments, mFOLFIRINOX
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

NCT02951819
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Sedona, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors

NCT03954067
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Advanced Cancer
Interventions
ASP9801, Pembrolizumab
Biological · Combination Product
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

NCT01397799
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
KX2-391
Drug
Lead sponsor
Kinex Pharmaceuticals Inc.
Industry
Eligibility
60 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Buffalo, New York • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 30, 2026, 9:02 PM EDT